Please assess the completion status of the following clinical trial:

Trial Title: Randomization of Botox for Stent Pain and Irritative Voiding Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients requiring unilateral ureteral stent insertion~* Age \> 18~* Renal/ureteral stones (single or multiple)~* Ureteral strictures~* Surveillance ureterscopy~* Willing and able to consent~* Willing and able to complete study questionnaires/diaries~* Willing to use CIC to empty the bladder at any time after study treatment if it is determined to be necessary by the investigator~Exclusion Criteria:~* History of malignancy~* Patients on medical therapy for benign prostatic hyperplasia (alpha blocker and/or 5alpha reductase inhibitor)~* Patients taking muscarinic-receptor antagonists (Ex. detrol, ditropan etc.)~* Patients who have an interstim sacral neuromodulator~* History of urinary retention~* Neurogenic or non-neurogenic detrusor overactivity~* Pregnancy~* Solitary kidney~* Insulin dependent Diabetes Mellitus (Uncontrolled Diabetes (HbA1c \> 8))~* Neuropathy~* History of transplant kidney~* History of narcotic abuse or chronic pain~* Anatomic bladder/ureteral abnormality~* Previous cystectomy/urinary diversion~* Conditions necessitating bilateral ureteral stents~* History of Interstitial cystitis~* Patients with a post-void residual volume of \> 100ml~* Patients with history of urinary retention~* Patients with active urinary tract infection~* Patients with history of chronic urinary tract infections~* Patients with concomitant use of any botulinum toxin within 3 months or any urological use of botulinum toxin in the past~* Patients with active genital infection, other than genital warts, either concurrently or within 4 weeks prior to screening~* Patients with concurrent or previously uninvestigated hematuria within 6 months prior to screening. -Patients with investigated hematuria may have entered the study if urological/renal pathology had been ruled out to the satisfaction of the investigator~* Patients with hemophilia, or other clotting factor deficiencies, or disorders that cause bleeding diathesis Patients with a known allergy or sensitivity to any botulinum toxin preparation (including study medication preparation), anesthetics, or antibiotics used during the study~* Patients with any medical condition that may have put them at increased risk with exposure to Botox including diagnosed myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Botox (Type: EXPERIMENTAL): The experimental group will include ureteral stent placement with three peri-ureteral injections of Botox A and fourteen site-specific intradetrusor injections of Botox A.
- Control (Type: NO_INTERVENTION): The control group will involve a ureteral stent placement with no injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).